Previous Close | 5.01 |
Open | 5.10 |
Bid | 5.08 x 500 |
Ask | 5.11 x 500 |
Day's Range | 4.98 - 5.18 |
52 Week Range | 4.71 - 12.43 |
Volume | |
Avg. Volume | 2,096,363 |
Market Cap | 736.106M |
Beta (5Y Monthly) | 1.38 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.54 |
Earnings Date | May 02, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 11.29 |
ROCKVILLE, Md. & EDMONTON, Alberta, April 30, 2024--The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
ROCKVILLE, Md. & EDMONTON, Alberta, April 16, 2024--UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
ROCKVILLE, Md. & EDMONTON, Alberta, April 15, 2024--Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024